Glofitamab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 140 publications

Advances in the clinical application of bispecific antibodies in cancer therapy.

Advances in the clinical application of bispecific antibodies in cancer therapy.

Journal: iScience

Published: January 01, 2026

Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma.

Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: December 24, 2025

Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas.

Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas.

Journal: Expert opinion on biological therapy

Published: December 12, 2025

Current progress and latest therapeutic options in immuno-oncology

Current progress and latest therapeutic options in immuno-oncology

Journal: Deutsche medizinische Wochenschrift (1946)

Published: October 28, 2025

Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US.

Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US.

Journal: Future oncology (London, England)

Published: October 21, 2025

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 20, 2025

Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study.

Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study.

Journal: Cancer biology & medicine

Published: September 30, 2025

T-cell engaging antibodies for B-cell lymphomas.

T-cell engaging antibodies for B-cell lymphomas.

Journal: Seminars in hematology

Published: September 21, 2025

What is established in the treatment of diffuse large B-cell lymphoma?

What is established in the treatment of diffuse large B-cell lymphoma?

Journal: Innere Medizin (Heidelberg, Germany)

Published: September 12, 2025

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Compassionate Use Program in Italy.

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Compassionate Use Program in Italy.

Journal: Hematological oncology

Published: August 26, 2025

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Journal: Seminars in hematology

Published: August 21, 2025

Exploration of adverse event profiles for glofitamab: A disproportionality analysis using the FDA adverse event reporting system.

Exploration of adverse event profiles for glofitamab: A disproportionality analysis using the FDA adverse event reporting system.

Journal: PloS one

Published: August 15, 2025

Showing 1-12 of 140

Last Updated: 02/24/2026